Ultibro Breezhaler

Ultibro Breezhaler

indacaterol + glycopyrronium

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Indacaterol 110 mcg, glycopyrronium 50 mcg
Indications/Uses
Once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients w/ COPD.
Dosage/Direction for Use
Special Precautions
Discontinue use if hypersensitivity reaction & paradoxical bronchospasm occurs. Not to be used in asthma & as rescue therapy. Narrow-angle glaucoma, urinary retention; CV disorders eg, CAD, acute MI, cardiac arrhythmias, HTN, convulsive disorders or thyrotoxicosis; patients unusually responsive to β2-adrenergic agonists. Hypokalaemia; hyperglycaemia. Not to be used concomitantly w/ long-acting β-adrenergic agonists & muscarinic antagonists. May affect ability to drive & use machines. Severe hepatic & renal impairment; end-stage renal disease. Pregnancy & lactation. Not to be used in ped patients <18 yr.
Adverse Reactions
Upper resp tract infection. Hyperglycemia, DM, hypersensitivity, nasopharyngitis, UTI, sinusitis, rhinitis, dizziness, headache, cough, oropharyngeal pain including throat irritation, dyspepsia, dental caries, pyrexia, chest pain, bladder obstruction including urinary retention.
Drug Interactions
Weakened or antagonised β2-adrenergic agonists effect. Not recommended w/ anticholinergics. Potentiated adverse events w/ sympathomimetic agents & possible hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics.
ATC Classification
R03AL04 - indacaterol and glycopyrronium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Ultibro Breezhaler inhalation powd cap
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in